ribonuclease A family member 11 (inactive)Genealiases: C14orf6 · HEL-S-84p · RAJ1
Q-omics provides the consensus-scored RNASE11 profile across patient tissues and cancer cell-line models. RNASE11 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RNASE11 is differentially expressed in 2, with the highest sampling consensus in THCA. Additionally, RNASE11 RNA expression shows 5,879 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, THCA, and STAD as cancer lineages where RNASE11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNASE11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNASE11 survival associations across molecular data types. RNASE11 RNA expression shows survival associations in the most cancer types (11), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNASE11 RNA expression–survival associations across cancer types. High RNASE11 expression shows unfavorable associations in SKCM, SCLC, LUSC, BRCA and UCS, but favorable associations in ACC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RNASE11 RNA expression.
This table summarizes RNASE11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RNASE11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNASE11 shows higher tumor expression in THCA and KIRC. The THCA box plot shows higher RNASE11 RNA expression in tumor versus normal tissue (log2 FC = +0.032, t-test p = .002).
This table shows molecular features associated with RNASE11 in patient tissues and cancer cell lines. In patient samples, RNASE11 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RNASE11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
